HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia.

Abstract
Classifying primary progressive aphasia (PPA) into variants that may predict the underlying pathology is important. However, some PPA patients cannot be classified. A 78-year-old woman had unclassifiable PPA characterized by anomia, dysarthria, and apraxia of speech without agrammatism. Magnetic resonance imaging revealed left mesial temporal atrophy and 18-flourodeoxy-glucose positron emission tomography showed left anterior temporal and posterior frontal (premotor) hypometabolism. Autopsy revealed a mixed tauopathy (argyrophilic grain disease) and transactive response-DNA-binding-protein-43 proteinopathy. Dual pathologies may explain the difficulty classifying some PPA patients and recognizing this will be important as new imaging techniques (particularly tau-positron emission tomography) are introduced and patients begin enrollment in clinical trials targeting the underlying proteinopathy.
AuthorsEoin P Flanagan, Joseph R Duffy, Jennifer L Whitwell, Prashanthi Vemuri, Dennis W Dickson, Keith A Josephs
JournalNeurocase (Neurocase) Vol. 22 Issue 1 Pg. 55-9 ( 2016) ISSN: 1465-3656 [Electronic] England
PMID25929342 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • DNA-Binding Proteins
  • TARDBP protein, human
  • tau Proteins
Topics
  • Aged
  • Aphasia, Primary Progressive (metabolism, pathology)
  • Atrophy (metabolism, pathology)
  • DNA-Binding Proteins (metabolism)
  • Female
  • Frontotemporal Lobar Degeneration (metabolism, pathology)
  • Humans
  • Magnetic Resonance Imaging
  • TDP-43 Proteinopathies (metabolism, pathology)
  • Tauopathies (metabolism, pathology)
  • tau Proteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: